Answers are grounded in this paper and cite their sources.
Background: We evaluated the diagnostic discrimination of serum endothelin-1 (ET-1), copeptin, and chemerin in adults evaluated for acute pulmonary embolism (PE). Methods: This prospective, single-center diagnostic study included 65 adults with CTPA-confirmed PE and 64 CTPA-negative controls recruited from the same emergency-department source population of patients evaluated for suspected PE. Controls were consecutively enrolled among dyspneic patients in whom CTPA excluded PE; no individual matching was used. Biomarkers were compared with D-dimer and the Wells score. Results: ET-1 was higher in the PE group (median, 12.96 vs. 6.41 pg/mL; p < 0.001) and showed moderate discrimination (AUROC, 0.731; 95% CI, 0.644–0.818), but was inferior to D-dimer (AUROC, 0.905; 95% CI, 0.852–0.958). Adding ET-1 to D-dimer changed the AUROC from 0.905 to 0.923 (DeLong p = 0.128), and adding ET-1 to Wells plus D-dimer changed it from 0.966 to 0.971 (DeLong p = 0.224). An age-adjusted D-dimer threshold preserved sensitivity (96.9%) and increased specificity from 48.4% to 56.3% relative to 0.50 mg/L FEU. Conclusions: ET-1 was associated with acute PE in this selected sample but did not materially improve discrimination beyond established comparators. Because the near-ceiling Wells–D-dimer model and selected sampling frame limit inference, external validation in an unselected diagnostic cohort is required.
No takes yet. Share an insight, caveat, or question.
Murat et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: